Develops nomlabofusp, a protein therapy intended to deliver frataxin to cells, for people with Friedreich’s ataxia, and uses its cell-penetrating peptide platform to pursue treatments for other rare diseases.
10-K for FY2025, filed Mar 19, 2026
No revenue reported yet.
10-K, filed Mar 5, 2020
10-Q for Q3 FY2026, filed Nov 16, 2026
−$31.1MView ↗
8-K, filed Nov 9, 2026
On November 9, 2026, the Company issued a press release announcing that the Company completed its rolling Biologics License Application…View ↗
8-K, filed Jun 29, 2026
On June 29, 2026, Larimar Therapeutics, Inc. (the “Company”) issued a press release announcing (i) that it has submitted the first module…View ↗
Competes with Biogen, Design Therapeutics, Lexeo Therapeutics, Neurocrine Biosciences, Voyager Therapeutics, Solid Biosciences, and PTC Therapeutics
10-K for FY2025, filed Mar 19, 2026The biopharmaceutical industry is characterized by intense and dynamic competition to develop new technologies and proprietary therapies.…View ↗
Loading...